KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 14 years of Shares Outstanding data on record, last reported at $256.6 million in Q3 2022.

  • For Q3 2022, Shares Outstanding changed 0.16% year-over-year to $256.6 million; the TTM value through Sep 2022 reached $256.6 million, changed 0.16%, while the annual FY2021 figure was $254.5 million, 2.08% down from the prior year.
  • Shares Outstanding reached $256.6 million in Q3 2022 per VRTX's latest filing, roughly flat from $256.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $260.2 million in Q3 2020 and bottomed at $254.5 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $257.2 million, with a median of $256.6 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: rose 2.4% in 2018, then fell 2.08% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $255.2 million in 2018, then grew by 1.49% to $259.0 million in 2019, then grew by 0.35% to $259.9 million in 2020, then dropped by 2.08% to $254.5 million in 2021, then increased by 0.83% to $256.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $256.6 million in Q3 2022, $256.0 million in Q2 2022, and $255.6 million in Q1 2022.